TONSL and breast cancer: Higher expression of TONSL mRNA was significantly associated with worse overall survival (OS) in lung adenocarcinoma, gastric cancer (intestinal and diffuse), breast cancer (luminal A, luminal B and HER2-positive) and ovarian cancer (endometrial and serous) (hazard ratios were greater than 1.2).